ARID1A and breast carcinoma: A clinicopathological analysis also revealed that 78% of TNBCs exhibit low ARID1A expression, and breast cancer with low ARID1A mRNA expression is associated with advanced tumors, increased p53 expression, and high Ki-67 expression (Zhang et al., 2012).